Human Trial Results Show Excellent Safety Data, Positive Immune Responses From GeoVax's DNA/MVA AIDS Vaccines
Tue, 06 Feb 2007 08:00 AM EST
... GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company, today reported successful early results from two ongoing AIDS prevention Phase I human vaccine trials. Results from the first low dose trial indicate a good safety profile as well as positive immune responses in human volunteers receiving 1/10th dose of GeoVax's AIDS vaccine. [click link for full article] ...
Related Topics
- Vaccines & Immunizations
- Immune System
- Acquired Immune Deficiency Syndrome
- Data & Statistics
- Chemical Safety
- Safety
- Clinical Trials
- Data Analysis
- Hearing Aids
- Factor IX
- Immune Deficiency
- HIV/AIDS & STDs
- National Data
- Food Safety
- Immune System/AIDS
- Drug Safety
- Fire Safety
- Child Safety
- Sports Safety
- Electrical Safety

Not Signed In -


